FAScinate Therapeutics are developing novel drugs for CNS disease area. Our KM-819 is a First-in-Class, Disease modifying drug candidate for neurodegenerative diseases such as Parkinson’s disease and Multiple System Atrophy to stop or slow down the disease progression.